Masoud Azodi

8.0k total citations · 1 hit paper
162 papers, 3.3k citations indexed

About

Masoud Azodi is a scholar working on Obstetrics and Gynecology, Oncology and Reproductive Medicine. According to data from OpenAlex, Masoud Azodi has authored 162 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Obstetrics and Gynecology, 52 papers in Oncology and 52 papers in Reproductive Medicine. Recurrent topics in Masoud Azodi's work include Ovarian cancer diagnosis and treatment (44 papers), Uterine Myomas and Treatments (43 papers) and Endometrial and Cervical Cancer Treatments (38 papers). Masoud Azodi is often cited by papers focused on Ovarian cancer diagnosis and treatment (44 papers), Uterine Myomas and Treatments (43 papers) and Endometrial and Cervical Cancer Treatments (38 papers). Masoud Azodi collaborates with scholars based in United States, Italy and Canada. Masoud Azodi's co-authors include Thomas Rutherford, Peter E. Schwartz, Alessandro D. Santin, Dan‐Arin Silasi, Elena Ratner, Stefania Bellone, Emiliano Cocco, Jessica N. McAlpine, Peter E. Schwartz and Natália Buza and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Masoud Azodi

155 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

2019 377 citations Masoud Azodi, Amit M. Oza et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Masoud Azodi United States	32	1.4k	1.2k	1.0k	809	531	162	3.3k
Kosei Hasegawa Japan	26	1.4k 1.0×	940 0.8×	1.0k 1.0×	678 0.8×	486 0.9×	179	3.0k
Stefania Cosio Italy	36	893 0.7×	1.7k 1.4×	1.5k 1.4×	729 0.9×	757 1.4×	118	3.4k
Prafull Ghatage Canada	29	855 0.6×	1.3k 1.1×	887 0.8×	845 1.0×	687 1.3×	110	2.9k
Margaret M. Steinhoff United States	34	1.0k 0.7×	1.5k 1.2×	1.2k 1.1×	874 1.1×	959 1.8×	77	3.9k
Tomoyasu Kato Japan	27	611 0.4×	802 0.7×	973 0.9×	986 1.2×	543 1.0×	194	2.9k
Claes G. Tropé Norway	36	1.2k 0.9×	1.2k 1.0×	928 0.9×	1.4k 1.7×	592 1.1×	149	3.8k
Robert Fruscio Italy	38	980 0.7×	2.7k 2.2×	1.9k 1.8×	1.2k 1.4×	1.0k 1.9×	195	4.9k
Carmen Tornos United States	38	916 0.7×	2.0k 1.6×	1.9k 1.8×	950 1.2×	621 1.2×	91	4.4k
Ivo Meinhold‐Heerlein Germany	27	528 0.4×	956 0.8×	589 0.6×	800 1.0×	343 0.6×	133	2.5k
Heidi J. Gray United States	28	2.7k 2.0×	1.4k 1.1×	689 0.7×	957 1.2×	612 1.2×	93	4.8k

Countries citing papers authored by Masoud Azodi

Since Specialization

Citations

This map shows the geographic impact of Masoud Azodi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masoud Azodi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masoud Azodi more than expected).

Fields of papers citing papers by Masoud Azodi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masoud Azodi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masoud Azodi. The network helps show where Masoud Azodi may publish in the future.

Co-authorship network of co-authors of Masoud Azodi

This figure shows the co-authorship network connecting the top 25 collaborators of Masoud Azodi. A scholar is included among the top collaborators of Masoud Azodi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masoud Azodi. Masoud Azodi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Erfani, Hadi, Carolyn Haunschild, Mitchell Clark, et al.. (2025). Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study. International Journal of Gynecological Cancer. 104440–104440.

Han, Chanhee, Blair McNamara, Stefania Bellone, et al.. (2023). The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology. 170. 172–178. 5 indexed citations

Mirza, Mansoor Raza, Gabriel Lindahl, Sven Mahner, et al.. (2022). Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Cancer Research Communications. 2(11). 1436–1444. 5 indexed citations

Zeybek, Burak, Emily Webster, Joan Tymon‐Rosario, et al.. (2021). Financial toxicity in patients with gynecologic malignancies: a cross sectional study. Journal of Gynecologic Oncology. 32(6). e87–e87. 14 indexed citations

Hui, Pei, et al.. (2019). Uterine tumor resembling sex cord stromal tumor - a case report with operative, immunohistochemical and imaging correlation. European Journal of Gynaecological Oncology. 40(5). 875–878. 1 indexed citations

Altwerger, Gary, Esther Borges Florsheim, Gulden Menderes, et al.. (2018). Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal of Cancer Research and Clinical Oncology. 144(12). 2449–2456. 20 indexed citations

Menderes, Gulden, Elena Bonazzoli, Stefania Bellone, et al.. (2017). Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Medical Oncology. 34(5). 91–91. 15 indexed citations

Altwerger, Gary, Gregory M. Gressel, Diana P. English, et al.. (2016). Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. Gynecologic Oncology. 144(1). 77–82. 30 indexed citations

English, Diana P., et al.. (2016). Chlamydia Peritonitis and Ascites Mimicking Ovarian Cancer. Case Reports in Obstetrics and Gynecology. 2016. 1–4. 5 indexed citations

10.

Ferrari, Francesca, Stefania Bellone, Jonathan Black, et al.. (2015). Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal of Experimental & Clinical Cancer Research. 34(1). 123–123. 31 indexed citations

11.

Schwab, Carlton L., Diana P. English, Jonathan Black, et al.. (2015). Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology. 139(1). 112–117. 26 indexed citations

12.

Lopez, Salvatore, Emiliano Cocco, Jonathan Black, et al.. (2015). Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. Molecular Cancer Therapeutics. 14(11). 2519–2526. 26 indexed citations

13.

Azodi, Masoud, et al.. (2013). EVALUATING THE NUTRITIONAL STATUS OF DORMITORY RESIDENT STUDENTS IN SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCE. scientific journal of ilam university of medical sciences. 21(3). 109–117. 1 indexed citations

14.

Craveiro, Vinicius, Yang Yang‐Hartwich, Jennie C. Holmberg, et al.. (2013). Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Medicine. 2(6). 987–987. 7 indexed citations

15.

Yu, Herbert, Thomas Rutherford, Masoud Azodi, et al.. (2012). Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal of Surgical Oncology. 107(2). 195–200. 46 indexed citations

16.

Richter, C., Emiliano Cocco, Stefania Bellone, et al.. (2010). High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. American Journal of Obstetrics and Gynecology. 203(6). 582.e1–582.e7. 29 indexed citations

17.

Fadare, Oluwole, et al.. (2010). Pleomorphic Rhabdomyosarcoma of the Uterine Corpus: A Clinicopathologic Study of 4 Cases and a Review of the Literature. International Journal of Gynecological Pathology. 29(2). 122–134. 27 indexed citations

18.

Richter, C., Pei Hui, Natália Buza, et al.. (2010). HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal of Clinical Pathology. 63(6). 544–547. 40 indexed citations

19.

Koyfman, Shlomo A., et al.. (2005). Adenoid cystic carcinoma of the cervix. Gynecologic Oncology. 99(2). 477–480. 21 indexed citations

20.

Rutherford, Thomas, et al.. (2004). Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to ≥ second line chemotherapy. Cancer Research. 64. 1028–1028. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact